gemcitabine has been researched along with Animal Mammary Carcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leung, J; St-Onge, P; Stagg, J; Suh, WK | 1 |
| Abramo, F; Lorenzo, RM; Marconato, L; Ratto, A; Zini, E | 1 |
| Bear, HD; Cha, E; Graham, L; Le, HK; Manjili, MH; Morales, JK | 1 |
| Bull, JM; Deng, W; Jenkins, GN; Rowe, RW; Strebel, FR | 1 |
| Carroll, J; Gurnani, M; Hajian, G; Johnson, RC; Mathis, JM; Nielsen, LL; Shi, B; Terracina, G | 1 |
5 other study(ies) available for gemcitabine and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Topics: Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Transplantation; Tumor Burden; V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 2017 |
Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dog Diseases; Dogs; Female; Gemcitabine; Infusions, Intravenous; Mammary Neoplasms, Animal; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2008 |
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
Topics: Animals; Antigens, Neoplasm; Carcinoma; Cell Growth Processes; Deoxycytidine; Drug Therapy; Female; Gemcitabine; Immune Tolerance; Immunotherapy, Adoptive; Lymphocyte Activation; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; T-Lymphocytes; Tumor Burden; Tumor Escape | 2009 |
The importance of schedule in whole body thermochemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hyperthermia, Induced; Mammary Neoplasms, Animal; Neoadjuvant Therapy; Rats; Rats, Sprague-Dawley | 2008 |
Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
Topics: Adenoviridae; Alkyl and Aryl Transferases; Animals; Antigens, Polyomavirus Transforming; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Bridged-Ring Compounds; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Farnesyltranstransferase; Female; Gemcitabine; Gene Transfer Techniques; Genes, p53; Mammary Neoplasms, Animal; Mice; Mice, Transgenic; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Phosphoric Monoester Hydrolases; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sequence Analysis, DNA; Taxoids; Time Factors; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2000 |